A recent study published in Human Vaccines & Immunotherapeutics highlights serious safety concerns related to three FDA-approved RSV vaccines: Pfizer’s Abrysvo, GSK’s Arexvy, and Moderna’s mRESVIA. This analysis, drawn from nearly 18,000 adverse event reports, identifies concerning health risks.
• Safety Signals:
• Pfizer’s vaccine reported 103 safety signals, including fetal death, pregnancy hemorrhage, and preterm birth.
• GSK’s vaccine had 91 signals, such as paralysis, Guillain-Barré syndrome, and mini-strokes.
• Both vaccines exhibited strong indicators of immune destruction (thrombocytopenia) and serious neurological damage, with certain conditions being significantly more likely than other vaccines.
• Moderna's Vaccine: Only 35 reports were available, making it difficult to assess its safety adequately.
• Specific Risks:
• GSK signals include a 120× increased likelihood of flaccid paralysis and 6.9× for Guillain-Barré syndrome.
• Pfizer indicates a 267× risk for premature delivery and a 33.8× risk for fetal death.
• Implications:
• The findings underscore potential risks to pregnant women and infants, corroborating previous clinical trial data.
Given the serious safety signals identified, there are calls for regulators to pause RSV vaccinations in seniors and pregnant individuals until these risks can be independently investigated. The current data raise significant concerns regarding the safety of these vaccines for vulnerable populations.
https://www.thefocalpoints.com/p/breaking-rsv-shots-linked-to-over
No comments:
Post a Comment